Skip to content
drillr.ai
Sign up

XLO

Xilio Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · US

$9.00
−0.22%
Ask drillr

  • Aug 12, 2026, 11:30 UTC

    Xilio Therapeutics received FDA clearance of its IND application for XTX501, a bispecific PD-1/masked IL-2 candidate.

    Source:

  • Aug 12, 2026, 00:00 UTC

    Xilio Therapeutics reported Q2 2026 collaboration and license revenue of $18.7 million, up from $8.1 million in Q2 2025, with a net loss of $6.4 million compared to a $15.8 million loss a year earlier.